Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
161.20
+1.77 (1.11%)
At close: Nov 20, 2026, 4:00 PM EST
165.79
+4.59 (2.85%)
After-hours: Nov 20, 2026, 7:58 PM EST
Revolution Medicines Revenue
Revolution Medicines had revenue of $197.56M in the quarter ending September 30, 2026. That makes Revolution Medicines the 17,602nd largest company in the world by revenue and 2,883rd in the United States.
Revenue (ttm)
$197.56M
Revenue Growth
n/a
P/S Ratio
176.49
Revenue / Employee
$223,736
Employees
883
Market Cap
34.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Exelixis | 2.50B |
RVMD News
- 1 day ago - Revolution Medicines presents updated Phase 1/2 data for RASONQUE - TheFly
- 1 day ago - Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 - GlobeNewsWire
- 5 days ago - Revolution Medicines says EC approves Rasonque in metastatic pancreatic cancer - TheFly
- 5 days ago - European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - GlobeNewsWire
- 5 days ago - Revolution Medicines Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - Revolution Medicines price target lowered to $247 from $272 at Morgan Stanley - TheFly
- 11 days ago - Revolution Medicines Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 15 days ago - Revolution Medicines price target raised to $350 from $280 at H.C. Wainwright - TheFly